NervGen Pharma Corp. Common stock (NGEN) Stock Forecast: StockMap's 2-Week Call
NGEN stock forecast: StockMap's model leans Underperform on NervGen Pharma Corp. Common stock for the two weeks after the Nov 19 close, toward NGEN trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 4 of 6 two-week windows on NGEN since Aug 24; by chance, a call on the same dates was right 63% of the time.
NervGen Pharma Corp. Common stock last closed at $1.92, +1.05% on the session.
Against the IVW growth benchmark the position is +3.38% over the forecast window.
NervGen Pharma Corp. Common stock's market cap is $206.62M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -39 (too close to call).
Where NGEN sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 3 bullish and 12 bearish.
Agreement across those insights is 80%.
42 daily calls for NGEN so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks NervGen Pharma Corp. Common stock in the 0th percentile on return on equity, where 100 is best.
NervGen Pharma Corp. Common stock is classified under Health Care / Pharmaceuticals.
StockMap tracks NervGen Pharma Corp. Common stock as the 91st largest of the 153 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.
Across that group the current two-week reads are 80 Moderate Underperform, 44 Neutral and 29 Strong Underperform.
On that composite NervGen Pharma Corp. Common stock ranks 91st of 153 in the group, against a group median of -0.36.